智通财经APP获悉，瑞士制药巨头诺华制药(NVS.US)周二表示，将以每股48美元的价格收购美国生物制药公司Tourmaline Bio(TRML.US)。这笔交易对Tourmaline Bio的估值为14亿美元。受此消息影响，Tourmaline Bio周二美股收涨近13%。 诺华制药在声明中表示，Tourmaline Bio专注于开发 ...

瑞士制药巨头诺华制药(NVS.US)周二表示，将以每股48美元的价格收购美国生物制药公司Tourmaline Bio(TRML.US)。这笔交易对Tourmaline Bio的估值为14亿美元。受此消息影响，Tourmaline Bio周二美股收涨近13%。 诺华制药在声明中表示，Tourmaline Bio专注于开发pacibekitug，这是一种 ...

周二，Tourmaline Bio(TRML.US)飙升超57%，创三年新高，报47.62美元。消息面上，诺华同意以约14亿美元的全现金交易收购该公司，Tourmaline的股东将在此交易中每股获得48美元，该公司将成为诺华的间接全资子公司。交易预计将在2025年第四季度完成。 诺华表示，此次 ...

About Tourmaline Bio Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with ...

智通财经APP获悉，周二，Tourmaline Bio(TRML.US)飙升超57%，创三年新高，报47.62美元。消息面上，诺华同意以约14亿美元的全现金交易收购该公司，Tourmaline的股东将在此交易中每股获得48美元，该公司将成为诺华的间接全资子公司。交易预计将在2025年第四季度完成。

Tourmaline Bio, Inc. announced its first quarter 2025 financial results, highlighting its ongoing Phase 2 TRANQUILITY trial which is set to reveal topline data in the second quarter of 2025. The trial ...

Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis. Tourmaline is developing TOUR006, its own IL-6 ...

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion.

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients ...

BERLIN (Reuters) - Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on ...

TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...

Tourmaline Bio (TRML) has been catching investor attention recently, even without a specific event driving the headlines. Sometimes, stocks start to move or attract renewed interest for reasons that ...